Metformin in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Phase 2 Trial (SAKK 08/09)

Basaria, 2006, Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy, Cancer, 106, 581, 10.1002/cncr.21642 Keating, 2012, Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer, J Natl Cancer Inst, 104, 1518 Smith, 2006, Insulin sensitivity during combined androgen blockade for prostate cancer, J Clin Endocrinol Metab, 91, 1305, 10.1210/jc.2005-2507 Ma, 2008, Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis, Lancet Oncol, 9, 1039, 10.1016/S1470-2045(08)70235-3 Flanagan, 2011, Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer, Ann Oncol, 22, 801, 10.1093/annonc/mdq443 Zakikhani, 2006, Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells, Cancer Res, 66, 10269, 10.1158/0008-5472.CAN-06-1500 Dowling, 2007, Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells, Cancer Res, 67, 10804, 10.1158/0008-5472.CAN-07-2310 Zakikhani, 2008, The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase, Cancer Prevent Res, 1, 369, 10.1158/1940-6207.CAPR-08-0081 Margel, 2013, Metformin use and all-cause and prostate cancer – specific mortality among men with diabetes, J Clin Oncol, 31, 3069, 10.1200/JCO.2012.46.7043 Goodwin, 2008, Insulin-lowering effects of metformin in women with early breast cancer, Clin Breast Cancer, 8, 501, 10.3816/CBC.2008.n.060 Ou, 2006, Metformin increases insulin sensitivity and plasma beta-endorphin in human subjects, Horm Metab Res, 38, 106, 10.1055/s-2006-925128 Romualdi, 2008, Metformin improves endothelial function in normoinsulinemic PCOS patients: a new prospective, Hum Reprod, 23, 2127, 10.1093/humrep/den230 Goldenberg, 2005, Metformin-diet benefits in women with polycystic ovary syndrome in the bottom and top quintiles for insulin resistance, Metabolism, 54, 113, 10.1016/j.metabol.2004.08.007 Cima, 2011, Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer, Proc Natl Acad Sci U S A, 108, 3342, 10.1073/pnas.1013699108 2001, ICH harmonized tripartite guideline: guideline for good clinical practice, J Postgrad Med, 47, 45 CTCAE v4.0 open comment period. National Cancer Institute, Cancer Therapy Evaluation Program Web site. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm Scher, 2008, Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group, J Clin Oncol, 26, 1148, 10.1200/JCO.2007.12.4487 Matthews, 1985, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man, Diabetologia, 28, 412, 10.1007/BF00280883 Templeton, 2013, Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08), Eur Urol, 64, 150, 10.1016/j.eururo.2013.03.040 Ryan, 2013, Abiraterone in metastatic prostate cancer without previous chemotherapy, N Engl J Med, 368, 138, 10.1056/NEJMoa1209096 Antonarakis, 2012, Changes in PSA kinetics predict metastasis-free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials, Cancer, 118, 1533, 10.1002/cncr.26437 Colloca, 2012, Prostate-specific antigen kinetics as a surrogate endpoint in clinical trials of metastatic castration-resistant prostate cancer: a review, Cancer Treat Rev, 38, 1020, 10.1016/j.ctrv.2012.03.008 Goodwin, 2002, Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study, J Clin Oncol, 20, 42, 10.1200/JCO.2002.20.1.42 Giovannucci, 2007, Metabolic syndrome, hyperinsulinemia, and colon cancer: a review, Am J Clin Nutr, 86, s836, 10.1093/ajcn/86.3.836S Wolpin, 2009, Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer, J Clin Oncol, 27, 176, 10.1200/JCO.2008.17.9945 Pollak, 2012, The insulin and insulin-like growth factor receptor family in neoplasia: an update, Nature Rev Cancer, 12, 159, 10.1038/nrc3215 Firth, 2002, Cellular actions of the insulin-like growth factor binding proteins, Endocr Rev, 23, 824, 10.1210/er.2001-0033 Butt, 2004, Insulin-like growth factor binding protein-3 expression is associated with growth stimulation of T47D human breast cancer cells: the role of altered epidermal growth factor signaling, J Clin Endocrinol Metab, 89, 1950, 10.1210/jc.2003-030914 Lubik, 2011, Insulin increases de novo steroidogenesis in prostate cancer cells, Cancer Res, 71, 5754, 10.1158/0008-5472.CAN-10-2470 Venkateswaran, 2007, Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts, J Nat Cancer Inst, 99, 1793, 10.1093/jnci/djm231 Zhu, 2008, Androgen receptor and growth factor signaling cross-talk in prostate cancer cells, Endocr Relat Cancer, 15, 841, 10.1677/ERC-08-0084 Goodwin, 2012, Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations, J Clin Oncol, 30, 164, 10.1200/JCO.2011.36.2723